Sam Tetlow, MBA
Chairman of the Board
Sam has a strong track record as a catalyst for life science company growth over the last 15 years and delivering returns in both management and investor roles. In addition to the Chairman role at BioFluidica, Sam is CEO of Grant Engine, a company located in Chapel Hill, N.C. that supports leading life science companies secure non-dilutive funding with win rates that are two to three times the national average. Sam has successful experience as an entrepreneur and investor in life sciences companies such as EpiCypher, where as CEO the Company was named best University Startup of 2016 by U.S. Congress, ILS Genomics (purchased by LabCorp), Immunologix (purchased by Intrexon), Gentris Corporation (Purchased by Cancer Genetics, Inc), and Tranzyme Pharma (IPO in April 2011), among others. Prior to that, Sam was a full time Partner with Research Triangle Ventures, where he led the full cycle of life science investing. Sam has a Bachelor of Science degree from Worcester Polytechnic Institute, honors, and a MBA from UNC Kenan-Flagler Business School.
Philip D. Buchanan, Ph.D.
Dr. Philip D. Buchanan, PhD., FACMGG is a Medical Geneticist and Clinical Cytogeneticist boarded by the American Board of Medical Genetics and Genomics and the American Board of Medical Specialists. He is Adjunct Professor of Obstetrics and Gynecology at the George Washington University. Dr. Buchanan graduated from North Carolina State University. Post-doctoral studies were completed at the University of Michigan, Harvard University and the University of Oregon. He joined the Department of Pediatrics at the University of North Carolina at Chapel Hill in 1970 to direct a new Prenatal Genetic Counseling Clinic and Cytogenetics Laboratory. Dr. Buchanan is a member of many professional societies. He presents at international meetings, publishes, moderates conferences, teaches, and serves as reviewer for peer-reviewed journals. He has served on college committees and as an NIH, FDA, NIEHS, and EPA Advisor. In 1983, Dr. Buchanan established GeneCare Medical Genetics Center in Chapel Hill. The Center had very active international research, clinical, laboratories and teaching programs. Dr. Buchanan served as Executive Vice President for Genetics at Alere. He has helped start and manage multiple private and public companies and foundations. He served as Chairman of the Board for Vestrics, a predictive business analytics corporation. He currently serves as the Chairman of the Board for Voices Together. He serves on the board of the Fetal Medicine Foundation of the USA and of Biofluidica.
Rolf Muller, Ph.D.
Chief Executive Officer
Rolf Muller is a biotechnology leader combining science and business knowledge to build and grow successful technology companies that further healthcare and the field of personalized medicine. He has structured and guided highly efficient multi-disciplinary research and commercial teams through funding, to product development, and successful product launch into global markets. Prior to joining BioFluidica he was the Founder and President of Biomatrica, which he developed from an idea to be a global leader in biopreservation technologies for diagnostic and health care companies. Over the last 16 years he has been involved in analyzing markets and developing strategies to position biotechnologies to maximize value. He has interacted with most of the major pharma and biotechnology companies to obtain funded development contracts, joint projects, and partnerships. In addition to raising successfully capital from investors he also raised non-dilutive capital from CDC, NCI, NIH, DARPA, In-Q-Tel and DOD. He obtained his Ph.D. in biochemistry from the Pasteur Institute in Paris France.
Steven A. Soper, Ph.D.
Cofounder and Chief Technology Officer
Dr. Steven A. Soper founded Biofluidica in order to develop new technologies to be used in the medical diagnostic, pathogen detection, and personalized medicine spaces. He is a worldwide recognized pioneer in the development of diagnostic platforms with over 12 years of experiences in the CTC research area along with being the author of five patents currently licensed by BioFluidica. He has over 310 peer-reviewed publications with an h-index of 56. In addition, he has generated over $60M in competitive research funding over his career with most of this funding focused on developing new technologies for in vitro diagnostics. Dr. Soper is currently the Foundation Distinguished Professor in Chemistry and Mechanical Engineering at Kansas University. He is also Director of the Center for BioModular Multi-scale Systems for Precision Medicine, which is focused on developing new tools for the molecular analysis of circulating biomarkers. He also holds an appointment at Ulsan National Institute of Science and Technology in Ulsan, South Korea, where he is a World Class University Professor.
Michael is an entrepreneurial healthcare and life sciences professional with 20 years of experience leading innovative business initiatives across the pharmaceutical, biotechnology and clinical laboratory industries by driving strategic vision, business partnerships and value-added product development. He has made significant impacts on the development and commercialization of over a dozen products in drug discovery & development, as well as several companion diagnostics and contributed to the production of a biopharmaceutical. He is currently the CEO of Inivata Limited, as well as the Founder and President of Personalized Medicine Partners LLC. Prior he was the CEO of On-Q-ity, and the Director of Business Development at GlaxoSmithKline.